Commercial Lead
About the job
- In-depth knowledge and a proven track record in setting strategy and launching therapeutic innovation in major pharmaceutical markets.
- A demonstrated track record in successfully growing commercial franchises.
- Significant contributions to successful strategic portfolio development, with breadth of experience across commercial, clinical development, and innovation.
- A strong external network and a deep understanding of healthcare policy management.
- The ability to manage complex projects with ambitious milestones in high-pressure circumstances.
- Strong analytical and strategic skills, good judgment, and the ability to make data-driven decisions.
- A sense of urgency inspired by science and a strong patient focus.
- An entrepreneurial approach, continuous learning, and a proven track record of pioneering new dimensions based on innovation.
- The ability to work at the forefront of real-world evidence, digital, patient engagement, and policy thinking, and to envision and shape these areas.
- The ability to co-create innovative solutions with internal and external stakeholders.
- The ability to learn and listen to others, with personal maturity.
- The ability to build on successful accomplishments.
- A proven track record of attracting, developing, and mentoring leaders, and the ability to inspire large, diverse, global teams to deliver results by creating shared purpose and community.
- An advanced degree in business, biological sciences, or medicine is valued.
- 15 years of experience in marketing and/or relevant commercial experience in the pharmaceutical or biotechnology industry.
- Experience effectively managing external agency partners and collaborating with cross-functional teams and internal and external stakeholders to implement strategies and programs.
- An understanding of the legal and regulatory environment in pharmaceutical promotions.
- Strong project management, communication, and organization skills.
- The ability to influence without authority and collaborate cross-functionally.
- The ability to work under pressure in a fast-paced environment and prioritize work to achieve positive results.
- Act as Commercial Asset Lead for FB102 and related projects, providing strategic leadership to the multifunctional FB102 Asset Team on lifecycle management, product strategy, and FB102 activities to maximize the medicine’s value throughout its lifecycle.
- Collaborate with global stakeholders across Market Access, Medical Affairs, Patient Advocacy, Health Economics and Outcomes Research, Clinical Science, CMC, Global Regulatory, Business Development, and Scientific Communications to implement pre-launch indication plans globally and in key regions and affiliates.
- Work with the FB102 Asset Clinical Development team to align clinical development and manufacturing plans strategically.
- Mobilize the organization to ensure regional launch readiness and implementation of global launch and pre-launch activities.
- Serve as the primary point of contact for regional General Managers, gathering unique market needs and insights and ensuring they are addressed.
- Ensure proper staffing of the FB102 commercial team and key sub-teams, including global marketing and commercial new product planning for pipeline indications.
- Experience growing commercial franchises in Celiac/Gastroenterology, Allergy, and/or Dermatology.
- US launch and global experience.
- Therapeutic expertise in Celiac/Gastroenterology, Allergy, or Dermatology.
About the company
argenx develops and markets antibody-based therapies for severe autoimmune diseases. Its medicines work by modulating the immune system through engineered antibodies, notably efgartigimod (VYVGART for generalized myasthenia gravis and VYVGART Hytrulo for CIDP) that influence FcRn pathways. The company differentiates itself through antibody engineering capabilities and a co-creation model with academic and industry partners, plus a pipeline focused on FcRn-, complement-, and target-directed programs across autoimmune indications. Its goal is to provide effective antibody medicines that improve patient outcomes and expand global access through its development and commercial footprint.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Amsterdam, Netherlands
Founded
2008
Get referred to argenx
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 product net sales hit $1.5 billion, up 60% year over year.
- Seronegative gMG approval and prefilled-syringe uptake expanded VYVGART's U.S. addressable market by 11,000 patients.
- Phase 3 readouts in ocular MG, myositis, and MMN create multiple 2026 catalysts.
What critics are saying
- VYVGART still drives nearly all value, leaving argenx exposed if MG demand stalls by 2027.
- Rivals in MG and complement biology pressure payer access, especially after broadening-label launches.
- If empasiprubart, adimanebart, and FB102 disappoint, argenx remains a one-franchise company.
What makes argenx unique
- VYVGART became first approved FcRn blocker across all gMG serotypes in May 2026.
- argenx has 18 straight quarters of growth, showing durable commercial execution through Q2 2026.
- The Forte Biosciences acquisition added FB102, broadening immunology reach beyond FcRn into CD122 biology.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%argenx to Present New VYVGART Data in MG and CIDP, Plus Pipeline Results, at AANEM 2026. 09/30/2026 Key Takeaways * argenx will present data on its portfolio and pipeline at the AANEM Annual Meeting and the MGFA Scientific Session, September 29 to October 2 in Orlando, Florida, including four oral presentations and dozens of posters. * New VYVGART (efgartigimod) results include deepening improvement in ocular myasthenia gravis (MG), sustained one-year efficacy in anti-AChR antibody-negative generalized MG (gMG), real-world data on earlier treatment, and long-term and switch data in chronic inflammatory demyelinating polyneuropathy (CIDP). * argenx will also present Phase 2 empasiprubart data in multifocal motor neuropathy (MMN) and Phase 1b adimanebart data in DOK7 congenital myasthenic syndrome (CMS). argenx, an Amsterdam-based immunology company, announced it will present clinical, long-term, and real-world data for VYVGART (intravenous efgartigimod alfa-fcab) and VYVGART Hytrulo (subcutaneous efgartigimod alfa and hyaluronidase-qvfc), along with results for two pipeline candidates. Chief Medical Officer Luc Truyen, M.D., Ph.D., said the data show how far the evidence for VYVGART reaches, across years of treatment and into patient populations historically left out of clinical trials. In MG, the company will present three sets of findings: * Ocular MG. In the Phase 3 ADAPT OCULUS study, patient-reported ocular scores on the Myasthenia Gravis Impairment Index (MGII) improved further after two VYVGART cycles beyond the placebo-controlled period. Scores went from -4.5 to -6.8 points in patients with anti-AChR antibodies and from -2.7 to -4.5 points in triple-seronegative patients. The company says the results build on evidence for VYVGART's potential as the first targeted treatment for ocular MG.
Argenx stock has gained roughly 14% year-to-date, with Wall Street analysts projecting a potential 23% upside over the next 12 months. The biotech company has delivered 18 consecutive quarters of revenue growth. In Q2 2026, Argenx's global product net sales surged 60% year over year to $1.5 billion, with a 17% quarter-over-quarter increase. The Vyvgart franchise, treating chronic autoimmune disorders, drives growth following May 2026 FDA approval making it the first treatment for all serotypes of adults with generalised myasthenia gravis. Approximately 24,000 US patients receive treatment for chronic inflammatory demyelinating polyneuropathy, with half not well-managed on current therapy. Argenx reported positive Phase 3 results for Vyvgart in ocular myasthenia gravis earlier this year, with regulatory filing underway.
Compliance Jobs Report: sept. 18. By Matt Kelly | September 18, 2026 This week the Compliance Jobs Report has a new top ethics and compliance dog at Uber, plus other hiring news at ATR, Argenx, Airbus, Bank of America, and several other places. Promotions to note at Kohler, RTX, Emerson, and more; job leads are in engineering, higher education, and banking. Plus its Meme of the Week! Radical Compliance gather the Jobs Report news items from LinkedIn, press releases, and wherever else Radical Compliance can find tips - and thank you to everyone who sends them in, you make the Jobs Report possible! If you have any gossip to share (even confidentially) email me at [email protected] or find me on LinkedIn. Compliance Jobs. This week Radical Compliance start with big news at Uber: the company has hired Matt Olsen as chief ethics, compliance, and security officer. Olsen comes to the ride-share giant from law firm Wilmer Hale, where he spent the last 18 months as chair of the firm's national security and government contracts practice; prior to that, he was assistant AG for national security at the Justice Department. Olson is the first permanent CCO at Uber since Scott Schools left the company in late 2024 to be head of compliance at OpenAI. (Technically, Heather Childs held the chief ethics and compliance role before Olsen; but she had been chief trust and security officer first and then Uber tacked the CCO title onto her portfolio before she left the company earlier this summer.) Michael Oren has joined Airbus as director of ethics and compliance. Oren previously worked at Lowe's Cos. as a director of compliance until earlier this spring. By the way, Radical Compliance is hearing still more rumors of departures within Centene Corp.'s compliance function, as first noted in last week's Jobs Report. Again, if you want to feed Radical Compliance more information, drop me a line at [email protected]! OneAscent, a financial services business in Birmingham, Ala., that caters to faith-based investment advisers, has named Monica Stoudemire chief compliance officer. Prior to OneAscent, Stoudemire was chief compliance officer at Bridgeworth Wealth Management, a Birmingham-based registered investment adviser with more than $2 billion in client assets. Ivana Popratnik has been hired at financial services firm Oanda as chief compliance officer. Popratnik comes to Oanda after four years at TastyFx, where she most recently had been compliance officer. Memorial Healthcare System in Hollywood, Fla., has hired Daniel Villavisanis as director of corporate compliance. Villavisanis comes to Memorial after not quite three years at United Surgical Partners International, where he had been a compliance officer. Bolton Clarke, an assisted-living healthcare system in Australia, has tapped Stephanie Brown as head of internal audit. Brown previously worked as director of audit, risk, and compliance at the Department of Natural Resources in Queensland. Michael Grace has delivered himself to shipping and logistics firm Freight Flex, where he is chief compliance officer. Grace comes to Freight Flex from Highway, a business that helps track the identities of freight carriers, where he had been vice president of customer risk management. Brian Stachow has joined Argenx as as associate director of ethics and compliance training. Stachow comes to the mid-sized biotech firm from Agilent Technologies, where he had been an instructional designer. Altruist, a "tech-forward wealth platform" for independent financial advisers, has hired Nina Karbaum as director of compliance. Karbaum formerly worked at FINRA (the regulator for broker-dealers) where she had been a regulatory examiner until August. French aircraft manufacturer ATR has hired Stefano Spanò as chief compliance officer. Spanò joins ATR, a maker of turbo-prop jets for regional travel, after 11 years at Italian defense contractor Leonardo, where he had most recently been a senior trade compliance officer. Emirates NBD, one of the larger banks in the Middle East, has tapped Mohammed Samir as chief audit executive for the bank's Egypt operations. Samir comes to Emirates from Abu Dhabi Commercial Bank, where he had also been chief audit executive since. 2020. Dhiman Biswas has a new job as senior manager of compliance analytics at Bank of America. Biswas previously worked at Collabera as a project management consultant and prior to that was a business analytics specialist at MassMutual. Curia, a contract manufacturing business in the pharmaceutical sector, has hired Vicki Jackson as quality compliance manager. Jackson was last seen at Otsuka ICU Medical, where she had been an audit manager. And Seth Herrington has joined Map Transit, a freight forwarding business in Florida, as compliance coordinator. Herrington had previously been in the U.S. Marine Corps working on regulatory compliance issues for the Office of the Inspector General and just wrapped up a college degree at the University of Central Florida. Welcome to the profession, Mr. Herrington. Moving up the ladder. Akuvo, a maker of AI-powered software for collections and credit risk management, has promoted Molly DeMarcus from senior launch adviser to model governance compliance analyst (a title I suspect Radical Compliance'll see more often in its AI-enhanced future). Bath and kitchen products manufacturer Kohler has promoted Dan Rieland from manager of codes and standards to senior manager for product regulatory compliance. Katelyn Weese has moved up the ladder at defense contractor RTX Corp. Weese had worked for several years in various roles supporting the RTX board; now she's associate director of the global ethics and compliance program. Electric equipment manufacturer Emerson has promoted Michael Gilchrist from senior associate general counsel to vice president for regulatory compliance. Rody Lingiah has a new role within the Capgemini empire. He had been an export control officer for the firm's Sogeti subsidiary; now he's export control manager for Capgemini Engineering. Siemens Healthineers has promoted Ievgeniia Vasylchenko to chief compliance officer for central and eastern Europe. Vasylchenko had previously ran compliance for Siemens' lab diagnostics business in the region and was regional compliance officer for Ukraine. Open req orders. Engineering and professional services giant KBR is seeking a staff attorney for its anti-corruption and business integrity team. Job can be based in either Houston or Arlington, Va.; salary range not provided. Looks like KBR is hiring for a few other ethics and compliance roles, too. Tufts University is looking for a privacy program manager. Job is based in Medford, Mass., just outside Boston. Salary range is $108,000 to $162,000. MVB Bank is hiring a director of fair banking compliance and enterprise compliance advisory. The job can be remote, although MVB's headquarters are in West Virginia. No salary range provided. #NotCool Compliance Meme of the Week. That's all for this week's report. As always, if you have a tip or want to brag about your new job, promotion, career milestone, or anything else, email me at [email protected] or find me on LinkedIn. I'm always happy to give credit to the many hard-working people here in its corner of the business universe. Posted in News
argenx SE, a global immunology innovation company, has appointed Thomas M. Brakel and Khurem Farooq as non-executive directors to its Board of Directors. The appointments were announced following the company's Extraordinary General Meeting of Shareholders. Tim Van Hauwermeiren, chairperson of the board, said the new directors bring valuable leadership and expertise as argenx works towards its Vision 2030 goals. The company develops antibody-based medicines for autoimmune diseases and has commercialised the first approved neonatal Fc receptor blocker. Voting results and related documents from the shareholders' meeting are available on the argenx website. The company partners with academic researchers to translate immunology research into treatments for diseases with high unmet medical needs.
BenchSci announces two-year enterprise agreement with argenx to advance ai-driven preclinical drug discovery. Scientist-led competitive selection deepens BenchSci's presence in European biopharma TORONTO - BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology innovation company, to deploy EMET, BenchSci's agentic research environment for preclinical drug discovery, within the organization. Selected through a competitive evaluation...